R Bataille, X G Zhang, J Wijdenes, J F Schved, B Klein
{"title":"Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia.","authors":"R Bataille, X G Zhang, J Wijdenes, J F Schved, B Klein","doi":"10.1007/BF02989668","DOIUrl":null,"url":null,"abstract":"<p><p>Because IL-6 has been involved in the pathogenesis of acute monoblastic leukemia, we investigated the in vitro anti-proliferative effect and the in vivo anti-tumoral effect of an anti-IL-6 murine monoclonal antibody (mAb) in a patient with M5B type acute leukemia. In the current study, we clearly show the IL-6 dependence of monoblastic cell viability and proliferation in vitro in short-term cultures of malignant cells and the clinical activity of the anti-IL-6 murine mAb. The complete neutralization of IL-6 in vivo was associated with a transient but complete disappearance of malignant monoblastic cells in the peripheral blood, with improvement or even normalization of several other biological parameters of disease activity. No immunization against the anti-IL-6 murine mAb was observed.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 4","pages":"185-8"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989668","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical oncology and tumor pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02989668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8
Abstract
Because IL-6 has been involved in the pathogenesis of acute monoblastic leukemia, we investigated the in vitro anti-proliferative effect and the in vivo anti-tumoral effect of an anti-IL-6 murine monoclonal antibody (mAb) in a patient with M5B type acute leukemia. In the current study, we clearly show the IL-6 dependence of monoblastic cell viability and proliferation in vitro in short-term cultures of malignant cells and the clinical activity of the anti-IL-6 murine mAb. The complete neutralization of IL-6 in vivo was associated with a transient but complete disappearance of malignant monoblastic cells in the peripheral blood, with improvement or even normalization of several other biological parameters of disease activity. No immunization against the anti-IL-6 murine mAb was observed.